Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Central Nervous System Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 17 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 137
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more

Conditions: Breast Cancer
Interventions: Left Ventricular Ejection Fraction; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 8
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
Interventions: Robotic-Assisted Surgery; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Human Papillomavirus Viruses, Papillomavirus Vaccines
Interventions: K-Talk Intervention (Storytelling and K-Bot), Storytelling Intervention, K-Bot Intervention, Written Information; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Thoracoabdominal Aortic Aneurysms
Interventions: TAAA Debranching Stent Graft System; Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Limb-girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Acute Myeloid Leukemia
Interventions: Fludarabine, Cytarabine, Gemtuzumab Ozogamicin, Azacitidine, Venetoclax; Drug
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: 29 Days to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 45
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more

Conditions: Thoracoabdominal Aneurysms
Interventions: Visceral Manifold and Thoracic Bifurcation, Unitary Manifold; Device
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Benign Prostatic Hyperplasia
Interventions: Data collection; Other
Lead sponsor: Urotronic Inc.; Industry
Eligibility: Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Tampa, Florida • Kearney, Nebraska • Omaha, Nebraska + 5 more

Conditions: Mantle Cell Lymphoma
Interventions: Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York • Charlotte, North Carolina • Seattle, Washington

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Oleclumab, Osimertinib, AZD4635; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Major Depressive Disorder
Interventions: Low Dose Psilocybin, Placebo, Medium Dose Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions: Dasatinib + Quercetin, Placebo Capsules; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stargardt Disease
Interventions: Not listed
Lead sponsor: AAVantgarde Bio Srl; Industry
Eligibility: 8 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Interventions: GSK4418959, PD-1 inhibitor; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more

Conditions: Hypertension, Stress, Psychological
Interventions: MIM-DASH, MIM Only, DASH Only; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity, Surgery
Interventions: Roux-en-Y Gastric Bypass, Vertical Sleeve Gastrectomy; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 25 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma
Interventions: Zimberelimab, Domvanalimab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: San Francisco, California • New Haven, Connecticut • Boston, Massachusetts

Conditions: COVID-19, Households, SARS CoV 2 Infection
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 374 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: Gene panel sequencing of tumor specimens; Other
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 541
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more

Conditions: Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
Interventions: Dostarlimab, Cobolimab; Drug
Lead sponsor: Meghan Shea; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Frontotemporal Dementia
Interventions: LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone; Biological · Drug
Lead sponsor: Prevail Therapeutics; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more

Conditions: Deafness With a Cochlear Implant
Interventions: Modified surgical approach, Cochlear Nucleus CI632 cochlear implant; Procedure · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

SP Thoracic IDE Study

Let's K-Talk - HPV Study for Ethnic Koreans

Visceral Manifold Study for the Repair of TAAA

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Visceral Manifold and Unitary Device Study for the Repair of Thoracoabdominal Aortic Aneurysms

OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

An Observational Study in Children and Adults With Stargardt Disease

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Stress and Blood Pressure Management for Caregivers

Effects of Weight Loss Surgery on Bone Health in Adolescents

AB154 Combined With AB122 for Recurrent Glioblastoma

ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases

Neuroblastoma Precision Trial

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Stimulating the Cochlear Apex Without Longer Electrodes